- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06813443
Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation (CMPMIRNA)
Clinical, Instrumental, and Molecular (Circulating and Tissue microRNAs) Characterization of Patients With Cardiomyopathy to Identify Critical Patients With Severe Organ Failure to be Candidates for Cardiac Transplantation
The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging techniques that may provide insights into the underlying disease mechanisms. By understanding these markers, the investigators hope to improve the way the investigators diagnose and manage CMP, particularly in terms of predicting progression to heart failure or heart transplantation.
The study will evaluate patients with hypertrophic cardiomyopathy (e.g., sarcomeric forms, Anderson-Fabry disease, AL, and TTR cardiac amyloidosis), dilated cardiomyopathy and arrhythmogenic cardiomyopathy. These patients will undergo clinical evaluations, including ECG, echocardiograms, CMR, biopsy analysis, and genetic testing, as well as molecular studies such as transcriptomics and miRNA analysis. This comprehensive approach aims to identify potential new biomarkers for diagnosing and predicting the disease course.
Study Overview
Status
Conditions
- Cardiomyopathies
- Heart Transplantation
- Laminopathies
- Fabry Disease
- Dilated Cardiomyopathy
- Sudden Cardiac Death
- Glycogen Storage Disease
- Hypertrophic Cardiomyopathy (HCM)
- Electrocardiogram
- Amyloidosis Cardiac
- Dystrophia Myotonica
- Infiltrative Cardiomyopathy
- Arrhythmogenic Cardiomyopathy
- Echocardiogram
- Cardiac Magnetic Resonance Imaging
- Mitochondrial Cardiomyopathy
- Micro RNA
Detailed Description
This is a non-pharmacological, national multicenter cohort study with both retrospective and prospective components.
For the prospective study, patients with CMP will be consecutively enrolled from the outpatient or inpatient settings of the IRCCS Azienda Ospedaliero-Universitaria di Bologna (coordinating center), Azienda Ospedaliero-Universitaria Careggi di Firenze, and the Department of Cardiothoracic and Vascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome. Enrollment will begin upon receipt of favorable opinions from the respective Ethics Committees and general management approvals at each center until the planned sample size is reached.
For the retrospective study, all patients managed at the aforementioned centers prior to obtaining Ethics Committee approval and general management clearance will be included.
The structured collection of the data necessary for the evaluation of the objectives will be carried out by creating a specific electronic database in which retrospective data will be collected starting from January 1, 1990, and for the prospective observation period from the moment of ethical committee approval and receipt of the clearance from the general director until December 31, 2027. The electronic archive may be used to obtain or confirm new scientific evidence in the field of CMP, particularly with reference to diagnosis, prognosis, and therapy. The electronic archive will be compiled through the consultation of the clinical records (outpatient or hospitalization), from which data regarding demographics, remote and recent medical history, family history, any genetic investigations, instrumental tests, information about symptoms at onset, and therapy will be collected. Aside from the analysis of miRNAs on tissues, which will be carried out for the study and will not in any way affect the patients' diagnostic-therapeutic path, all instrumental exams and therapies that patients will undergo are part of standard clinical practice. Any genetic investigations that patients may undergo are part of the regular care pathway and will be performed when clinically indicated, or if a precise etiological diagnosis is necessary, with consequent therapeutic implications, in the differential diagnosis between various forms of CMP, and when, in the context of familial forms, it may be useful for family screening. Patients will be enrolled during hospitalization or at the outpatient visit. After obtaining informed consent, patients will be evaluated based on clinical needs. There is no minimum duration for following the patient. In a subgroup of patients enrolled in the prospective study, additional molecular evaluations will be carried out on plasma and cardiac tissue. The blood sample-taken as per clinical practice-will be processed within 4 hours through centrifugation. After isolation, the plasma will be divided into aliquots of 500 µL and stored at -80°C. In the subpopulation of the study undergoing endomyocardial biopsy (diagnostic) or cardiac surgery (e.g., myectomy, valve replacement, etc.), according to the standard-of-care, fresh cardiac tissue will be collected. The cardiac tissue (taken during endomyocardial biopsy/cardiac surgery performed according to clinical practice) will be partially immersed in formalin and sent, as per normal procedure, to pathology where it will be processed for paraffin embedding, and a small fragment will be frozen and immediately embedded in OCT (optimal cutting temperature) and stored at -80°C. RNA will then be extracted and analyzed using NGS (next-generation sequencing) of small RNA, ddPCR (droplet digital Polymerase Chain Reaction), and spatial transcriptomics.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Elena Biagini, MD, PhD
- Phone Number: +39051214483
- Email: elena.biagini@aosp.bo.it
Study Contact Backup
- Name: Silvia Palmieri, M. Sc.
- Phone Number: +39051214483
- Email: silvia.palmieri@aosp.bo.it
Study Locations
-
-
Emilia-Romagna/Bologna
-
Bologna, Emilia-Romagna/Bologna, Italy, 40138
- Recruiting
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
-
Contact:
- Elena Biagini, MD, PhD
- Phone Number: +39 051 214 4483
- Email: elena.biagini@aosp.it
-
Contact:
- Silvia Palmieri, M.Sc.
- Phone Number: +39 051 214 4483
- Email: silvia.palmieri@aosp.bo.it
-
-
Lazio/Roma
-
Roma, Lazio/Roma, Italy, 00161
- Not yet recruiting
- Dipartimento di Scienze Toraciche Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCSS di Roma
-
Contact:
- Francesca Graziani, MD
- Phone Number: +39 0630154639
- Email: francesca.graziani@policlinicogemelli.it
-
-
Toscana/Firenze
-
Firenze, Toscana/Firenze, Italy, 50134
- Not yet recruiting
- Azienda Ospedaliero-Universitaria Careggi di Firenze
-
Contact:
- Iacopo Olivotto, MD
- Phone Number: +39 3333314844
- Email: iacopo.olivotto@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
The study plans to enroll a population of 700 patients affected by CMP evaluated both in the inpatient and outpatient regime, at
- IRCCS AOUBO (n=520)
- Azienda Ospedaliero-Universitaria Careggi of Florence (n=90)
- Department of Thoracic Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCSS of Rome (n=90)
Description
Inclusion Criteria:
- Patients diagnosed with CMP according to current international guidelines
- Age ≥ 12 years at the time of diagnosis
- Obtaining informed consent from the patient and the parent or legal guardian (in the case of patients aged < 18 years)
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
risk stratification
Time Frame: Enrollment in the prospective phase and collection of data for the retrospective phase: 30 months; Follow-up: 2 years, Data analysis: 6 months
|
Accuracy of clinical, instrumental, histological, and molecular variables in identifying critical CMP patients or those at risk of organ transplantation. For each marker and their combinations, specificity, sensitivity, and AUC will be assessed. Unit of Measurement: sensitivity, specificity, and Area Under the Curve (AUC) |
Enrollment in the prospective phase and collection of data for the retrospective phase: 30 months; Follow-up: 2 years, Data analysis: 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gene expression profile (transcriptomics) and microRNA analysis
Time Frame: Enrollment in the prospective phase: 30 months, Follow-up: 2 years, Data analysis: 6 months
|
The tissues analyzed will consist of blood (plasma microRNA) and cardiac tissue (MicroRNA Quantification and Spatial Transcriptomics) on endomyocardial biopsy/cardiac surgery samples performed for diagnostic/therapeutic purposes. These analysis will allow us to evaluate transcripts specific to each cell and/or small groups of cells by mapping their location within the tissue organization. Gene expression data will be explored in association with the tissue images using dedicated analysis software Unit of Measurement: number of miRNA copies/µL |
Enrollment in the prospective phase: 30 months, Follow-up: 2 years, Data analysis: 6 months
|
|
AL (Light Chain Amyloidosis) vs TTR (Transthyretin) differential diagnosis in cardiac amyloidosis
Time Frame: Enrollment: 30 months; Data analysis: 6 months
|
Development of a diagnostic model integrating clinical (NYHA class), instrumental (left ventricle mass in g/m², BNP in pg/mL, Troponin in ng/dL), and molecular (miRNA copies/µL) variables to differentiate AL vs TTR cardiac amyloidosis. Unit of Measurement: sensitivity, specificity, and Area Under the Curve (AUC) |
Enrollment: 30 months; Data analysis: 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Elena Biagini, MD, PhD, IRCCS Azienda Ospedaliero-Universitaria
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Aortic Valve Disease
- Musculoskeletal Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Muscular Diseases
- Pathologic Processes
- Pathological Conditions, Anatomical
- Heart Diseases
- Neuromuscular Diseases
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Neurodegenerative Diseases
- Heart Valve Diseases
- Heredodegenerative Disorders, Nervous System
- Lipid Metabolism Disorders
- Genetic Diseases, X-Linked
- Aortic Stenosis, Subvalvular
- Aortic Valve Stenosis
- Muscular Disorders, Atrophic
- Carbohydrate Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Proteostasis Deficiencies
- Brain Diseases, Metabolic, Inborn
- Brain Diseases, Metabolic
- Lipid Metabolism, Inborn Errors
- Cardiomegaly
- Heart Arrest
- Death, Sudden
- Lysosomal Storage Diseases, Nervous System
- Cerebral Small Vessel Diseases
- Sphingolipidoses
- Lipidoses
- Muscular Dystrophies
- Myotonic Disorders
- Laminopathies
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Hypertrophy
- Myotonic Dystrophy
- Amyloidosis
- Cardiomyopathy, Dilated
- Death, Sudden, Cardiac
- Death
- Glycogen Storage Disease
- Fabry Disease
Other Study ID Numbers
- CMPMIRNA
- RC-2022-277327/RC-2024-2789983 (Other Grant/Funding Number: Italian Ministry of Health)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.